Hudson Bay Capital Management LP Akebia Therapeutics, Inc. Transaction History

Hudson Bay Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$2.22 - $3.78 $543,900 - $926,100	-245,000 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$2.39 - $13.08 $107,550 - $588,600	45,000 Added 22.5%	245,000 $615,000
Q2 2020 Aug 12, 2020	BUY	$6.67 - $13.58 $300,150 - $611,100	45,000 Added 29.03%	200,000 $2.72 Million
Q1 2020 May 14, 2020	BUY	$4.1 - $10.24 $225,499 - $563,200	55,000 Added 55.0%	155,000 $1.18 Million
Q4 2019 Feb 12, 2020	BUY	$3.16 - $6.73 $316,000 - $673,000	100,000 New	100,000 $632,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.